ATE176472T1 - Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält - Google Patents

Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält

Info

Publication number
ATE176472T1
ATE176472T1 AT95920456T AT95920456T ATE176472T1 AT E176472 T1 ATE176472 T1 AT E176472T1 AT 95920456 T AT95920456 T AT 95920456T AT 95920456 T AT95920456 T AT 95920456T AT E176472 T1 ATE176472 T1 AT E176472T1
Authority
AT
Austria
Prior art keywords
nalbuphine
pct
producing
containing little
epimer
Prior art date
Application number
AT95920456T
Other languages
English (en)
Inventor
Frank Kavka
Original Assignee
Mallinckrodt Chemical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Chemical Inc filed Critical Mallinckrodt Chemical Inc
Application granted granted Critical
Publication of ATE176472T1 publication Critical patent/ATE176472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95920456T 1994-05-31 1995-05-16 Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält ATE176472T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25146094A 1994-05-31 1994-05-31

Publications (1)

Publication Number Publication Date
ATE176472T1 true ATE176472T1 (de) 1999-02-15

Family

ID=22952064

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920456T ATE176472T1 (de) 1994-05-31 1995-05-16 Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält

Country Status (11)

Country Link
US (1) US5756745A (de)
EP (1) EP0763038B1 (de)
JP (1) JP4040673B2 (de)
AT (1) ATE176472T1 (de)
AU (1) AU699114B2 (de)
CA (1) CA2191843C (de)
DE (1) DE69507697T2 (de)
ES (1) ES2127532T3 (de)
HU (1) HU224914B1 (de)
NZ (1) NZ287243A (de)
WO (1) WO1995032973A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19622866C2 (de) * 1996-06-07 1998-12-24 Viva Diagnostika Diagnostische Verwendung von Opiat-Antagonisten und -Agonisten enthaltende Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
GB9717629D0 (en) * 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6114370A (en) * 1998-09-28 2000-09-05 Wall, Jr.; William H. Amnesic sedation composition and method of administering same
WO2006084389A1 (de) * 2005-02-11 2006-08-17 Cilag Ltd. Verfahren zur reinigung von noroxymorphon-verbindungen
ES2357216T3 (es) * 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
ES2629766T3 (es) 2006-04-21 2017-08-14 Nektar Therapeutics Reducción estereoselectiva de una morfinona
ATE493416T1 (de) * 2007-05-04 2011-01-15 Mallinckrodt Inc Verbessertes verfahren zur herstellung von 6- alpha-hydroxy-n-alkylierten opiaten
AU2008276385B2 (en) * 2007-07-17 2013-07-18 SpecGx LLC Preparation of N-alkylated opiates by reductive amination
WO2010017573A1 (en) * 2008-08-11 2010-02-18 Tasmanian Alkaloids Pty Limited PROCESS FOR MAKING MORPHINAN-6α-OLS
NZ607842A (en) 2008-09-30 2013-12-20 Mallinckrodt Llc Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
JP5824448B2 (ja) 2009-04-24 2015-11-25 ブロック ユニバーシティ モルフィナンおよびモルフィノン化合物の調製法
ES2465066T3 (es) * 2009-06-11 2014-06-05 Mallinckrodt Llc Aminación reductora de 6-ceto-normorfinanos por transferencia de hidrógeno catalítica
EP2440562B1 (de) * 2009-06-11 2016-08-10 Mallinckrodt LLC Herstellung von 6-alpha-amino-n-substituierten morphinanen durch katalytischen wasserstofftransfer
GB0914338D0 (en) 2009-08-17 2009-09-30 Johnson Matthey Plc Improved process
JP5867081B2 (ja) * 2010-01-29 2016-02-24 東レ株式会社 胆道疾患の治療又は予防剤
CN103717601A (zh) 2011-06-09 2014-04-09 马林克罗特有限公司 通过催化氢转移对6-酮基吗啡喃的还原胺化
BR112014005421A2 (pt) 2011-09-08 2017-04-04 Mallinckrodt Llc produção de alcaloides sem o isolamento de intermediários
PL3063152T3 (pl) * 2013-11-01 2020-01-31 SpecGx LLC Dogodne wytwarzanie n-podstawionych morfinan-6-oli z morfinan-6-onów
PL3065743T3 (pl) * 2013-11-07 2019-12-31 SpecGx LLC Sposób wytwarzania 6-hydroksymorfinanów bez izolowania związków pośrednich
CN110305142B (zh) * 2019-07-12 2021-11-16 宜昌人福药业有限责任公司 一种6β-羟基吗啡衍生物的立体选择性合成方法
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113845526B (zh) * 2021-01-18 2022-11-08 四川大学 一种蒂巴因衍生物及其制备方法和应用
CN112759596B (zh) * 2021-01-05 2022-03-15 宜昌人福药业有限责任公司 一种纳布啡的制备方法及其中间体
WO2023150579A2 (en) * 2022-02-01 2023-08-10 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing nalbuphine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
IL26896A (en) * 1966-01-19 1970-11-30 Endo Lab 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) * 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine

Also Published As

Publication number Publication date
HUT77409A (hu) 1998-04-28
NZ287243A (en) 1997-12-19
DE69507697D1 (de) 1999-03-18
HU9603289D0 (en) 1997-01-28
AU2590295A (en) 1995-12-21
EP0763038B1 (de) 1999-02-03
AU699114B2 (en) 1998-11-19
JPH10501223A (ja) 1998-02-03
DE69507697T2 (de) 1999-06-10
HU224914B1 (en) 2006-04-28
JP4040673B2 (ja) 2008-01-30
CA2191843C (en) 2006-05-02
WO1995032973A1 (en) 1995-12-07
CA2191843A1 (en) 1995-12-07
ES2127532T3 (es) 1999-04-16
EP0763038A1 (de) 1997-03-19
US5756745A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
ATE176472T1 (de) Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält
DE59507973D1 (de) Verfahren zur herstellung von umhüllten tabletten
AU6124696A (en) Control method for processes of synthesis of chemical products
ATE149196T1 (de) Verfahren zur herstellung von olefinen
DE59004931D1 (de) Verfahren zur Herstellung intumeszenzfähiger Formteile.
DE68910083D1 (de) Verfahren zur Herstellung von harten Konfektprodukten, die hauptsächlich Xylitol enthalten.
ATE190050T1 (de) Verfahren zur herstellung von 2-acetyl-1-pyrrolin in verkapselter form, zwischenprodukte und endprodukt
DE69022788D1 (de) Verfahren zur Herstellung von Polysiloxandichtungen.
DE69418581D1 (de) Verfahren zur herstellung dünner bleche, geeignet für die anfertigung von dosenteilen
DE68913030D1 (de) Verfahren zur Herstellung von Propylen.
DE69822663D1 (de) Invert- bohremulsion, die durch umwandlung von olefinen hergestellte mischungen von sekundären estern enthält, und verfahren zur herstellung
ATE200544T1 (de) Fachwerk und gefacheelement und verfarhren zur herstellung eines gefacheelements
HUP9601321A3 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
ATE152722T1 (de) Verfahren zur herstellung von 9-(2-hydroxy)- ethoxy-guanin
ATE108618T1 (de) Verfahren und vorrichtung zur herstellung von beta-kasein.
DE58900821D1 (de) Verfahren zur herstellung von phosphororganischen derivaten des 2,4-di-t-butylphenols, der 4,4'-dihalogenmagnesium-verbindungen des biphenyls und die verwendung der phosphororganischen derivate zur stabilisierung von kunststoffen, insbesondere in polyolefinformmassen.
DE59307795D1 (de) Verfahren zur herstellung von rückstandsfreiem 2,4/2,6-diaminotoluolgemisch
DE69328043D1 (de) Verbessertes Verfahren zur Herstellung von 1,3-Butylenglykol
AU1237592A (en) Iloprost effective against cerebral malaria
DE69514122D1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
ATE135342T1 (de) Verfahren zur herstellung von diacetylrhein
DE69009394D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethyl-1-cyclohexanon.
DE59301021D1 (de) Verfahren zur kontinuierlichen Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.
ATE173259T1 (de) Verfahren zur herstellung von indolizinderivaten
ATE192437T1 (de) Verfahren zur herstellung von 3-amino-2-chlor-4- alkyl- bzw. 4-cycloalkyl-pyridine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties